Milestone Pharmaceuticals
MIST
43 hedge funds and large institutions have $22.9M invested in Milestone Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 10 closing their positions.
817% more call options, than puts
Call options by funds: $743K | Put options by funds: $81K
142% more capital invested
Capital invested by funds: $9.46M → $22.9M (+$13.5M)
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
0% more funds holding
Funds holding: 43 → 43 (0)
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
0.06% less ownership
Funds ownership: 22.16% → 22.1% (-0.06%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBM
Propel Bio Management
Los Angeles,
California
|
+$453K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$282K |
| 3 |
SAM
Simplify Asset Management
Las Vegas,
Nevada
|
+$187K |
| 4 |
Goldman Sachs
New York
|
+$159K |
| 5 |
VFA
Valeo Financial Advisors
Carmel,
Indiana
|
+$148K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$258K |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$200K |
| 3 |
Morgan Stanley
New York
|
-$197K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$142K |
| 5 |
LPL Financial
San Diego,
California
|
-$134K |
MIST Hedge Fund Activity: Q2 2025 in Review
43 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q2 2025, worth a combined $22.9M — up 142% from $9.46M a quarter earlier.
Fund positioning in MIST was balanced in Q2 2025: 10 funds opened new positions, 10 closed out, 10 added to existing stakes and 9 trimmed.
The largest buyer was Propel Bio Management, adding an estimated $453K. The largest seller was Millennium Management, exiting entirely with an estimated $258K sold.
- 43 institutional investors held Milestone Pharmaceuticals (MIST) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $22.9M of Milestone Pharmaceuticals stock for Q2 2025, up 142% quarter-over-quarter.
- 10 funds opened new Milestone Pharmaceuticals positions in Q2 2025 and 10 closed out, a net change of 0 holders.
- The largest Milestone Pharmaceuticals buyer in Q2 2025 was Propel Bio Management, an estimated $453K added.
- The largest Milestone Pharmaceuticals seller in Q2 2025 was Millennium Management, an estimated $258K sold.
Based on aggregated 13F filings for Q2 2025.